Neighborhood is a community of entrepreneurs, innovators, regulatory experts, healthtech consultants and industry KOLs working together to help biotech & medtech startups achieve their next significant valuation milestone.
Meet Our Community
NEIGHBORS
2025
Deep brain stimulation and recording for neurological disorders and brain function analysis
Belgium
ATLAS Neuroengineering
ATLAS Neuroscience is focused on developing advanced implantable neural devices. Located on the imec-campus in Leuven (BE), with robust partnerships including imec & the University of Leuven, ATLAS is positioned at the forefront of innovation in the neurotechnology sector, with strong emphasis on smart implantable devices for better brain function understanding and treatment.
ATLAS develops next-gen smart neural devices that enable high-precision brain mapping and modulation, using pioneering human trials with temporary array implantations in patients undergoing brain surgery.
Blue Bees Therapeutics
Blue Bees Therapeutics’ mission is to develop immunomodulatory antibodies to treat cancers, utilizing antibody-based ligands affecting immune cells. Their lead drug candidate, BB10X, has been shown effective in controlling tumors in five different in vivo models. BBTx has a proprietary discovery platform for optimized antibody-based drugs and obtained an exclusive worldwide license for their technology, patented by CEA in 2020, via SATT Paris-Saclay.
Curlim
Curlim is a biotech company developing small molecules to treat peripheral neuropathies. Their project is focused on the development of an innovative compound, CLM001, designed to treat a range of peripheral neuropathies including Charcot-Marie-Tooth disease 1A (CMT1A). Current therapeutic strategies for these conditions are limited and symptomatic, lacking a pharmacological treatment. CLM001 has shown significant improvement in neurological symptoms in 2 animal models without apparent toxicity: motor nerve conduction speeds significantly improved, as well as the animals’ balance and motor skills.
Severe pain (chemotherapy-induced peripheral neuropathy)
France
Dolinnov
Dolinnov aims to develop an innovative therapeutic approach to treat chronic pain, particularly neuropathic and inflammatory pain. The company specifically targets a new site within the peripheral nervous system, focusing on a protein named FXYD2 expressed specificaly in the dorsal root ganglia (DRG).
Dolinnov is the first company worldwide to target this site for pain treatment using an antisense oligonucleotide (ASO) with a lipid modification formulation.
ErVimmune
ErVimmune is a biotech company focused on developing revolutionary cancer vaccines and T cell-based therapies targeting non-conventional tumor antigens, specifically those derived from human endogenous retroviruses (HERVs). Their mission to address unmet medical needs by creating innovative immunotherapies for “cold” tumors, which are typically resistant to standard checkpoint inhibitors. ErVimmune utilizes a cutting-edge platform that combines bioinformatics, proteomics, and immunological approaches.
Onco/Neuro/Antimicrobial/ Chronic disease
France
IASO Discovery
IASO Discovery is a biotech specializing in the discovery and preclinical development of oligonucleotide-based treatments. Backed by an innovative technological platform developed over 20 years of research in the Philippe Barthélémy laboratory at Bordeaux University, IASO’s business model is based on a balance of partnerships, co-development and in-house programs. Their ambition is to become a key player in the field of oligonucleotide-based drugs, transforming research into genuine therapeutic advances.
Detection/quantification of CTDNA by molecular means from free dna extracted from plasma
France
METHYS Dx
METHYS Dx focuses on developing innovative liquid biopsy tests, designed to detect unique molecular signatures for various types of cancer.
The company aims to provide fast and ultrasensitive blood tests for dynamic monitoring of cancer, facilitating real-time clinical assessment.
Their target is cancer follow-up and their first product is liquid biopsy tests that utilize molecular signatures and ultra-sensitive detection technology to analyze tumor markers in biological fluids. These tests are designed to be less invasive than tissue biopsies and provide prognostic information, track tumor evolution, and help in the therapeutic follow-up of patients.
2024
Neuropathy
France
Apateya
Apateya develops innovative non-opioid therapeutic solutions with the aim of treating the symptoms of neuropathic patients.
Artemix
ArtemiX develops a novel, patented drug delivery formulation for the local sustained release of active drug intended to prevent stenosis of bypass surgery and arteriovenous fistula (AVF).
Postoperative complications (stenosis, occlusions), occur in up to 50% of cases, leading to intimal hyperplasia, lumen narrowing and access failure, associated with increased morbidity, mortality and healthcare costs.
ArtemiX intends to prevent vessel stenosis and increases the primary patency success rate.
bYoRNA
bYoRNA’s mission is to democratize mRNA therapies by producing high-quality mRNA in a cost-efficient and scalable fashion. bYoRNA is developing a genetically engineered bioproduction platform to turn living cells into factories producing abundant, highly stable and non-immunogenic mRNA.
Celeos SAS
Celeos conceive an innovative medical device for oncological surgeon guidance, offering real-time, accurate information on tissue states to reduce unnecessary reoperations and patient uncertainty.
Having the size and form of an ultrasound trolley, Celeos’ device is based on the use of a laser to sample the tissue surface without contact, mass spectrometry (an analytical method to obtain the tissues characteristic signatures) and machine learning algorithms to give a classification to surgeons in real time.
This technology goes beyond the current limitations of the gold standard pathological examination, and the other guidance tools being developed.
Aiming to improve human and animal health while minimizing its environmental footprint, Celeos is a mission-driven company committed to social and environmental action.
e-sensia
e-sensia (formerly ECHO-AI) develops deep-tech software that employs voice analysis for patient triage and AI-powered medical evaluations, examining both the content and sound of the voice. It facilitates informed decision-making by automatically detecting the level of urgency, probability of hospitalization, suggesting crucial diagnostic elements, conducting real-time voice-based quality control, and proposing questions that save time, ensure safety, and even enhance humanity. Additionally, it relieves responders of administrative tasks by automatically filling in medical forms, allowing them to focus on providing care.
Colorectal cancer, IBD, other GI tract diseases
France
Plantibodies
Plantibodies is developing orally delivered immunotherapies to fight against GI tract diseases. The company has developed a platform to produce monoclonal antibodies in edible plants. The leaves are then lyophilized in powder and put into a capsule for oral administration. Once in the colon, the plant cellulose is degraded by the microflora, releasing the antibodies locally. Their platform can address several diseases, such as colorectal cancer (our first candidate), IBD, etc.
Acute Liver Pathologies, Ocular and Neurodegenerative conditions
France
SeaBeLife
SeaBeLife is a French preclinical stage biotechnology company specialized in the development of First-In-Class drugs based on platform technology, that block regulated necrosis cell death pathways in order to protect or regenerate organs affected by severe pathologies – for which there are no alternative, effective treatments. The company primarily targets acute pathologies of the liver, whilst leading other research activities in ocular and neurodegenerative conditions. It already demonstrated in vivo proof of concept for two molecules in two indications: Acute Liver Injuries and Dry-AMD with a clinical development expected to start mi-2024 in the Liver and 2026 in the Eye. SeaBeLife also obtained promising preliminary results with other molecules in in cellular models of Neurodegenerative diseases.”
Oncology, Neurology, Rare diseases
France
Syntopia
Syntopia develops a techbio platform that combines high-throughput phenotypic screening on a microfluidic system and in silico models to explore new therapeutic options for diseases whose biological models are too complex to be systematically tested in vitro. It allows to explore new treatments options for complex in vitro models, with first applications in oncology, neurology, and rare diseases. We will aid pharmaceutical and biotech firms to discover new drug, diseases pathways and find new relevant hits for identified targets, leading to expansion of therapeutic arsenal for treating patients with unmet clinical needs.
Neurological diseases
France
Therasonic
TheraSonic develops a medical device that enables drug delivery to the brain in the context of incurable neurological diseases.
Our non invasive solution uses neuro-navigated ultrasound to temporarily and locally disrupt the blood-brain barrier. Main innovations include real time dose adjustment and robotic targeting to treat multiple brain volumes.
Twinical
Twinical develops a medical software to provide digital assistance while planning and performing soft-tissue surgery.
Surgical planning is based on patient-specific digital 3D models of the organ, computed from standard CT/IRM images. Unlike existing solutions, these models are not static, but interactive: they can be visualized and manipulated with augmented-reality glasses, virtually annotated, deformed and cut to simulate the real tissue behavior.
Oncology
France
Yomi Pharma
Yomi Pharma is a young biotechnology start-up harnessing the power of sortilin biology to improve patients’ lives.
We are developing new therapeutic assets based on the endogenous properties of sortilin. Our first candidate, YomiPep-01, targets lung cancer, which is highly aggressive despite recent medical advances.
2023
Medical Device
France
Myotact
Myotact is a non-invasive medical device intended to limit phantom limb pain for amputees.
The device is designed in the form of a bracelet allowing it to be positioned on the lower and upper parts of the limbs. It allows the acquisition of muscle activity with 8 EMG (surface) sensors and is coupled with vibro tactile feedback (known as sensory feedback) with 8 vibrators to stimulate the sensorimotor loop.
MS Insight
MSInsight, a healthtech company, is empowering the fight against cancer by revealing actionable information from the genome.
MSICare is a next-generation sequencing-based in vitro diagnostic device for detection of microsatellite instability (MSI) using DNA isolated from formalin-fixed paraffin-embedded (FFPE) or frozen tumor tissue, matched with or without normal specimens from patients with solid or liquid malignant neoplasms.
Kyron Bio
kyron.bio’s mission is to unclog bottlenecks in therapeutic protein production, allowing better drugs to reach patients.
Kyron.bio is developing a genetically engineered bioproduction platform that enables production of novel, cheaper and better biopharmaceuticals.
Colofact
ColoFact is developing a novel point-of-care medical device for Colorectal Cancer screening with Minimal interaction with faeces and discrete handling allowing Instant analysis and sample homogeneity. The result is available on phone app or national digital Health platform.
Colofact aim to increase screening participation rate, with a novel and innovative solution that reduces the current barriers to achieving the target screening rates, and reduce healthcare costs.
InVenis
InVenis Biotherapies is a biotech company, spin-off from academic laboratory U1172 and Taipei Medical University, developing innovative regenerative therapies based on blood platelet. Thanks to the high therapeutic potential of our product, we target the most severe diseases involving cell death, as the amyotrophic lateral sclerosis.
Ilonov
ILONOV develops first-in-class biotherapies to prevent and cure diabetes based on the action of a muscle-secreted hormone, which has shown outstanding therapeutic potential in protecting pancreatic islets in islet transplant and in Type 2 Diabetes.
Ektah
EktaH is a deeptech biotechnology start-up committed to scientific innovation to reduce food intake and thus body weight in obese individuals.
The company’s scientific approach consists of identifying lipid “lures (or agonists)” capable of activating the oro-gustatory receptors more intensely than dietary fatty acids, thus allowing the brain to trigger early satiety, which will immediately result in a reduction in food intake. These lures do not provide calories and would also trigger a more intense food pleasure than that created by fatty foods naturally consumed.
CaleeTech
CaleeTech’s technology facilitates patients’ quality of life in
conjunction with diabetic guidelines. Patients can consume
nutritional intakes without significantly increasing their weight or
blood sugar levels.
CaleeTech’s technology is a unique and optimized oral
formulation that helps patients temporally avoid absorbing
excess calories and glucose. The process can be repeated as
needed and is safe, transient, and affordable.
MDsim
MDSIM offers medical device companies and spine surgeons an immersive end-to-end solution to develop, simulate and implement the optimal treatment for spine deformities.
The software uses the latest Artificial Intelligence (AI) and Computer Modeling & Simulation (CM&S) technologies to generate and use a hi-fidelity, biomechanical, digital twin of the patient spine.
The Surgeon will use the software to simulate and optimize the surgery on the digital twin of the patient before implementing on the actual patient in the operation room.
The use of in-silico medicine (i.e. MDSIM software using AI and CM&S to build and use the digital twin) improve the patient QoL and reduces the risk of post-operation complications and even re-operation.
Allogenica
Allogenica is a biotechnology start-up, evolving in the world of Immuno-oncology with a focus on blood cancers.
Allogenica develops universal cell therapies with the potential to treat all
eligible patients, safer and at drastically reduced manufacturing costs.
Okomera
Okomera is pioneering automation and miniaturization of personalized tumor biopsy studies. The technology was invented and patented by our co-founders at Ecole polytechnique.
Okomera’s 3D technology is currently used for testing patient samples and will later on be included in clinical trials.
2022
Robeauté
Today, more than 1 billion people are affected by neurodisease and as we live longer this number will continue to grow. Tackling the disease when its still small and localized has the potential to change treatments entirely. Local solutions are emerging but lack the way of being delivered on site.
At Robeauté, we are creating a tiny microrobot to access hard-to-reach locations of the brain, to deliver those innovative therapies exactly where they are needed, at the right dosage. The ability to go locally, with 3D motility, submillimeter precision and live-data collection will set our device above the current gold standard and pave the way for new minimally invasive, therapeutic solutions – both tools and molecules.
Usense
Usense is a Medtech offering an innovative and miniaturized technology in Medical biology. With one click, Usense allows to measure precisely in urine the majority of health parameters which are usually analyzed in medical biology labs. By capitalizing on AI and machine learning, Usense detects presence of markers fostering early diagnosis in medical consultation, emergency contexts and pathology follow up.
PepKon
PepKon is redefining cancer therapy with first-in-class peptides, inspired by the power of human biology.
PepKon has built a cutting–edge platform at the intersection of biology, chemistry, and artificial intelligence. This platform enables the in–house design, optimization, synthesis, and testing of new drug candidates.
PepKon’s mission is to address the limitations of current treatments by creating safer and more effective therapies.
In oncology, they’re committed to advancing breakthrough solutions for refractory and incurable cancers.
Omini
Omini is a medtech company transforming chronic disease management with connected blood testing. Their patented, sensor-based technology enables near-patient testing and self-testing while keeping providers informed every step of the way. Combining multi-sensing blood testing strips, a portable connected reader, and an application for clinical and biological data transmission, Omini’s unique technology is a giant leap forward for precision medicine, and a powerful catalyst in the shift towards preventive care.
Womed
Womed is pioneering innovative, safe and effective treatments to free women from challenging uterine pathologies: infertility, uterine bleeding, endometriosis.
Rare inherited nephropathies and retinopathies
Paris, France
Medetia
Medetia is a biotech company, localised at the Imagine Institute in Paris, specialized in the research of new innovative molecules for pediatric ciliary pathologies. Medetia implements a discovery process based on cell-based pharmacological assays from patients, redevelopment research of molecules known from regulatory agencies, and its own medicinal modulation chemistry. Medetia proposes MDT-110, its first molecule in pre-clinical development for pediatric nephronophthisis and targets improvements of the renal and retinal lesions, specific to this pathology.
AtmosR
AtmosR develops innovative therapeutic treatments for patients suffering from severe, disabling and often fatal neurological diseases, based on the Ondine syndrome model. The Ondine syndrome is a rare genetic disorder of the central nervous system, patients suffer from severe and sometimes fatal hypoventilation episods. The company relies on the skills of 7 partner laboratories, worldwide specialists in their field. The development of a treatment for the Ondine syndrome is used to develop treatments for other severe CNS disorders presenting similar cellular mechanisms.
Beams
Accuracy of the operatory gesture is an essential step in solid tumor’s care. Beams develops intraoperative probes for surgeons, to help them localising precisely and in real time potential tumor residues – thanks to beta particles detection – and removing them while preserving surrounding sound tissues. Offered to health facilities with a nuclear medicine department, these probes are aimed to better preserve patients’ quality of life by improving the surgical gesture.
ZenzeTech ApS
Parkinson’s Disease is a neurodegenerative condition that affects +10 million people worldwide. Parkinson’s only gets worse with time, and with more than 50% not getting the optimal treatment, patients experience a serious downfall in quality of life. At Zenze we made it our mission to improve the quality of life for people with Parkinson’s through intelligent insoles that monitor patients’ gait symptoms and course of disease to personalise their treatment.
2021
AIINTENSE
AiiNTENSE optimizes the management of patients with acute or chronic neurological pathology, more particularly peri-resuscitation or associated with covid-19.
Based on the automated collection of clinically relevant elements of the patient record, AiiNTENSE platform is able to assist in the diagnosis and treatment of neurological pathology as well as its prognostic evaluation and follow-up, using a multimodal platform that integrates a health data portal, cognitive assistants, a monitoring application and a tele-expertise and teleconsultation network. It allows hospitals to guarantee full traceability of procedures, to reduce bed occupancy time and to save medical staff time.
The platform integrates outputs of specialized medical devices and algorithms developed in collaboration with medical R&D centers.
HEMERION
Each year, in Europe and in the US, more than 20,000 patients undergo surgery for a brain cancer. This condition remains incurable, but the quality of surgery significantly improves survival. The combination of a photosensitizer drug and a laser illumination device makes it possible to treat disseminated and inaccessible cancer cells during surgery. This technology offers new perspectives and developments on brain cancer therapy are already under clinical evaluation.
The proof of concept is established, the absence of toxicity is demonstrated and the first trials in humans show an improvement in patient survival. In this context, Hemerion aims to market this new modality for 2026.
AGENT
AgenT is on a mission to detect Alzheimer’s when it can be prevented through a simple blood test. To prevent the onset of symptoms or stop the progression, we need to diagnose Alzheimer’s long before dementia.
By combining multi-omics biomarkers signals with machine learning, AgenT identifies Alzheimer’s patients that no other current diagnostic tool can detect.
They envision a future where routine health screenings include a blood test for Alzheimer’s to slow down the disease’s progression before it’s too late.
ILIOMAD
iliomad Health Data is a service company that enhances the value of health data for medical research by enabling simple and secure reuse. iliomad Health Data renders health data compliant (iliomad GDPR-Data Protection), informs patients of their data reuse (iliomad Patient Information) to promote the ethical and transparent sharing of data (iliomad Data Community and iliomad Data Portal). Our aim is to contribute to the reuse of data for medical research.
Iliomad, which means infinity in Gaelic, carries this ambition. Our mission is to unleash, through regulatory compliance, the power of data to serve a single purpose: to contribute to scientific progress while ensuring patient engagement.
Orixha
Orixha is a start-up developing a breakthrough technology for ultra-fast cooling of patients after cardiac arrest, by total liquid ventilation.
BIOPHTA
Lack of adherence to Rx eye drops is the #1 Unmet Medical need in Ophthalmology. Poor treatment compliance leads to a worse progression of Eye Diseases. We will change lives of patients suffering from chronic eye diseases by creating a best-in-class solution reducing treatments burden.
Our drug delivery technology will disrupt the entire ophthalmic market by:
• solving compliance with a once a week only application
• topical & easy to apply solution
• continuous accurate dosing with efficacy in multiple indications
Our non-invasive topical ocular insert is aimed at several ophthalmic indications by allowing more effective treatments and better control of diseases.
Cartilages regeneration
Lausanne, Switzerland
Vanarix
We solved a key problem encountered in cell therapy using chondrocytes (cartilagecells): the dedifferentiation and loss of function of cells during expansion in culture. Thanks to our patented technology, dedifferentiated chondrocytes regain their full capacity to synthesize a hyaline matrix.
Bubble removal for safer intravenous infusion
Ireland
Gasgon Medical
Intravenous therapy is the most common invasive therapy in healthcare, with 3.7 billion disposable IV tubes used each year, and complications from air bubbles are frequent and present serious risks of adverse events for patients. Gasgon Medical is developing ALOTIS, a closed-system aspirator device to safely remove bubbles from IV drugs including toxic chemotherapy drugs, thereby protecting patients and healthcare workers from occupational exposure, a key initiative of the European Health policy makers. Gasgon has plans to enter the market in Europe by 2022, with clinical study plans in place through its hospital partners.
Antibiotic Resistance
Paris, France
Diotheris
Diotheris develops anti-infective microbes to prevent bacterial infections and reduce the spread of antibiotic resistance. Our two lead products target intermittent and persistent Staphylococcus aureus nasal carriage. Fields of application include prevention of peri-operative S. aureus infections, prevention of catheter infections in dialysis patients, prevention of severe infections in chronic carriers of MRSA (Methicillin Resistant S. aureus)
Neurologie (X-fragile)
Bordeaux, France
SoXtra
Fragile X Syndrome (FXS) is the first cause of monogenic autism and the second cause of intellectual disability after Trisomy 21. The pathophysiological pathway of BKCa channel is a major therapeutic pathway with a high level of proofs in the human clinical genetics, in vivo and in vitro. SoXtra develops the first treatment that acts as BKCa channel activator and offer a personalized approach for each patient with:
- AS212 drug repositioning , having as objective to restore the behavioral and cognitive phenotype , as well as the sensory hyperexcitability of FXS patients
- Specific biomarker for intention to treat
- Specific biomarker for efficacy evaluation and follow-up.
Flowbone
We want to make fragility hip fractures history with a bioactive gel, that is injected into the hip bone via a mini-invasive procedure and strengthens the bone quickly through a unique “bone-seeding” process.
Our 3 selling points :
– Minimal-Invasive application in outpatient setting
Our product can be injected into the hip bone under local anesthesia and fluoroscopic control in a procedure similar to a bone biopsy. No general anesthesia is required.
– Highly flowable, bone-friendly formulation
Its innovative formulation makes our product highly flowable. It can be injected into trabecular bone at a low pressure without a prior tissue removal, which is important for the preservation of the bone tissue and biology.
– Very simple application and handling
Our product is delivered ready-for-use in a pre-filled syringe to the clinician. It can be stored at room temperature and has a shelf life of 2 years (according to preliminary data, to be confirmed). The radiologist can take it out of the box and inject it with a standard bone access needle.
2020
TreeFrog Therapeutics
TreeFrog Therapeutics is a stem cell company that will enable millions of patients to access the medical revolution of cell therapies by overcoming current critical manufacturing issues.
TreeFrog Therapeutics has developed C-Stem™ : a proprietary technology platform that provides an end to end 3D scalable solution that will dramatically reduce treatment costs.
Through strategic partnership and co-developments, TreeFrog Therapeutics will help cell therapy players to secure cell production and quality, fasten clinical development and facilitate market access.
Industrie pharmaceutique
Pessac, France
OP2 DRUGS
OP2 Drugs SAS (“OP2″) is a biotech company that aims at developing innovative life-saving drugs for unmet medical needs, especially in the cardiology field. Our first patented compound, OP2113, which targets mitochondrial dysfunction, is in preclinical stage, with a strong scientific rational.
Based on strategic partnerships in Europe and in the US, we are generatling growth and value for all stakeholders thanks to our drug candidates pipeline, in several indications. OP2 is planned to move forward to clinic in 2018.
Located in Pessac, close to Bordeaux (France), OP2 Drugs is supported by Unitec (Bordeaux), managed by Frédéric Marin (CEO) and Nicolas Pineau (COO), and funded by ambitious financial players.
AiScreenings
AiScreenings (formerly AiVision) has assembled the best academic and scientific team to reduce blindness in the world.
The initial research focused on diabetic retinopathy (the leading cause of blindness in France and worldwide).
They are continuing their work on Glaucoma and AMD and other medical indications will follow.
They will help advance science in the knowledge and treatment of retinal diseases.
Their diagnostic assistance tools accelerated by federated Artificial Intelligence are acclaimed by Ophthalmologists and Health Professionals recognize the relevance of our solution.
AiScreenings contributes to improving screening and reducing medical deserts.
Their solution has been operational in France since 2017.
OP2LYSIS
Op2Lysis develops the first treatment for hemorrhagic stroke a life-threatening disease that affects >1,5M people every year worldwide.
Op2lysis program aims at demonstrating the clinical efficacy and safety of its therapeutic solution to be ready to enter advanced phases of development by 2023.
Op2Lysis is a biotech company dedicated to the development of innovative products to improve the benefit of thrombolytic treatment in stroke, the first cause of acquired disability worldwide. Christophe GAUDIN and Jérôme PARCQ are the co-founders of Op2Lysis, which benefits from their complementary experiences and skills.
NEUROPHOENIX
Neurophoenix is a biotechnology company developing a revolutionary treatment for chronic and acute optic neuropathies such as glaucoma or retina ischemia. This novel approach is based on a molecule derived from a virus that has the remarkable property of reactivating the survival mechanism of injured neurons.
Our molecule is the result of many years of academic research carried out by Monique Lafon, director of the Viral Neuro-immunology laboratory at Institut Pasteur.
This research identified a molecule produced by the rabies virus with the remarkable capacity to both keep neurons alive (neuroprotection) and also stimulate axon regrowth from damaged neurons (neuroregeneration).
Pharmacodynamic Modeling and Artificial Intelligence
Paris, France
HILLO
Hillo develops the first AI-based decision support platform for diabetic patients, based on a blood glucose levels predictive system that adapts to every patient’s physiology and habits.
Our technology combines pharmacodynamic modeling and artificial intelligence, we develop tools for patients to help them anticipate and avoid hypo- or hyperglycemia, and for care teams to help them understand each patient’s specific glycemic response. We’ve demonstrated outstanding results and accuracy of our predictive technology through trials in hospitals.
Partners
BusinessFrance
Business France is the national agency serving the internationalization of the French economy. It is responsible for the international development of companies and their exports, as well as prospecting and reception of international investments in France.
Created on January 1, 2015, Business France is the result of the merger of UBIFRANCE and AFII (French Agency for International Investments). Business France has 1,500 employees located in France and in 70 countries. It relies on a network of public and private partners.
Paris, France
Lehub.bpifrance.fr/accompagnement-healthtech/://bpifrancelehub.fr/healthtech
LE HUB BPI FRANCE – HEALTHTECH
Bpifrance’s HealthTech Hub aims to better connect companies in the sector to their ecosystem to promote their growth and development.
The Hub’s HealthTech accelerator focuses on supporting Bpifrance’s post-seed biotech, medtech and e-health participations by offering them a tailor-made program, adapted to issues specific to the sector (development time, regulatory issues, capital needs, etc.).
LallianSe
LallianSe is an innovation integrator and venture builder that has supported more than 100 companies since its inception, almost a decade ago.
Their mission: to build the environment that enables the successful development of healthcare innovations through the articulation of equity stories.
LallianSe designs tailor-made journeys for institutions, companies, hospitals and entrepreneurs, with an active, agile approach and a team of 50 Experts and Entrepreneurs-in-residence.
Through their agility and original initiatives, LallianSe nurtures privileged relationships to form a one-of-a-kind partnership network within the life sciences, for the benefit of the companies it supports.
LallianSe’s approach is part active collaboration (co-creation of companies, capital acquisition), part long-term support services.
In conjunction with all stakeholders in the French and European innovation environment, they regularly intervene with boards of directors, investors, and strategic actors.
CNRS Innovation
CNRS Innovation, established in 1992, is a French public limited company, now a subsidiary of the CNRS at 90% and 10% Bpifrance Financement. Its mission is to transfer innovative technologies, mainly originating from the CNRS, to the industry. Its action extends from the receipt of projects to the granting of exploitation rights through consulting in Intellectual Property strategies, participation in the filing of patent applications, seeking of industrial partners, negotiating and drafting of exploitation agreements, and management of patent portfolios. CNRS Innovation proposes services and products developed through its strong acquired expertise in the analysis and management of innovative projects in the following areas:
- Technology evaluation
- Technology transfer
- Patent mapping
- Technology scouting
- Intellectual Property consulting and management
MATWIN
MATWIN (Maturation & Accelerating Translation With Industry) is the only French open-innovation platform specifically dedicated to oncology. MATWIN, a wholly owned subsidiary of Unicancer group (gathering all the French Comprehensive Cancer Centres) has offered – for over 15 years – several actions (expertise, acceleration program, events, etc.) aimed at accelerating the development of innovative projects dedicated to the fight against cancer. MATWIN has supported more than 300 projects and led to the creation of more than 50 startups.
Paris-Saclay Cancer Cluster
TECHNION – ISRAEL INSTITUTE OF TECHNOLOGY
The Technion – Israel Institute of Technology is a public research university in Haifa, Israel. Established in 1968, the Faculty of Biomedical Engineering has a multidiciplinary scope nurturing research activities that blend medical and biological engineering. Research projects have resulted in the development of patented medical aids. Recent research breakthroughs include the identification of a structured neurological code for syllables and could let paraplegics “speak” virtually through the connection of the brain to a computer.
EIT Health
EIT Health was established in 2015, as a ‘knowledge and innovation community’ (KIC) of the European Institute of Innovation and Technology (EIT). The EIT is made up of various KICs who each focus on a different sector, or area, of innovation – in our case, that is health and aging. The idea behind the EIT KICs is that innovation flourishes best when the right people are brought together to share expertise. The so called ‘knowledge triangle’, is the principle that when experts from business, research and education work together as one, an optimal environment for innovation is created.
iPEPS Incubateur
The Institut du Cerveau et de la Moelle épinière – Institut du Cerveau – ICM (Brain & Spine Institute) – is an international brain and spinal cord research center whose innovative concept and structure make it the only institute of its kind in the world. The Institut du Cerveau – ICM brings patients, doctors and researchers together with the aim of rapidly develop treatments for disorders of the nervous system and enable patients to benefit from them as quickly as possible.
AI For Health
We aspire to boost new initiatives in companies and to see the emergence of new collaborations around artificial intelligence projects. This initiative is an opportunity to allow various actors of both ecosystems, health and artificial intelligence, to meet up and share their experiences to drive AI innovation forward.
PMT
The PMT is managed by manufacturers whose objective is to represent, animate and federate companies with microtechnical know-how serving the various markets.
Prevent2Care
The Fondation Ramsay Santé, the Pfizer Innovation France endowment fund and INCO have joined forces to support innovative entrepreneurial and associative projects that strengthen access to prevention through Prevent2Care, an accelerator and a regional prize that rewards innovative associations in this field: the Prevent2Care Tour.
WE SUPPORTED THEM
WEFIGHT
Wefight is a company specialized in the development of virtual assistants for patients & their relatives. Wefight’s goal is to create companions that answer questions from patients & their loved ones, that make information simple and that are accessible anywhere and at any time during the care journey.
THERAPANACEA
TheraPanacea is a highly ambitious artificial intelligence-powered French spinoff medical technology company exploiting state-of-the-art research technology with origins from Ecole CentraleSupelec, Inria, and Gustave Roussy Institute. TheraPanacea brings to the radiation therapy market the latest inter-disciplinary technological advances from the associated research laboratories endowed with an excellent IP portfolio (international patents & protected software) and validated at the proof of concept level through prestigious clinical collaborations. Our ART-Plan solution is the first fully AI-powered solution to deliver radiation therapy.
PK VITALITY
PKvitality is an advanced bio-wearable company working on solutions to real problems like diabetes.
OPHTAI
OphtAI, a joint-venture between two key industrials, aims at revolutionizing the screening and diagnostic of eye pathologies thanks to its state-of-the-art solution based on artificial intelligence.
Fall detection
Villeneuve Loubet
ELLCIE HEALTHY
Automatic detection of sudden or soft falls thanks to sensors in the glasses.
EKINNOX
DOMALYS
Our mission is to improve the lives of people in care and those around them. To achieve this, we work with people in the field who are faced with industry challenges to design wonderful products
Interventional NeuroRadiology
Paris, France
BASECAMP VASCULAR
Basecamp Vascular was born out of the realization that the catheters used for interventional vascular procedures are, due to their length and flexibility, difficult to control. Their handling leads to loss of time due to the need for precision, the difficulties of progression to the target zone, and the safety constraints associated with the procedure.
The objective of this project is to make catheters activatable to improve their navigation capabilities and to speed up the speed of treatment placement while ensuring the safety of the procedure during the intervention.
AQEMIA
Aqemia is a deep-tech start-up in drug discovery. We are building on breakthrough physics theory and unique software to find promising drug candidates among millions of molecules.
Archeon Medical
Archeon Medical’s mission is to help caregivers bring patients back to life using artificial intelligence to improve the patient’s ventilation. Archeon’s EOlife®, is an easy-to-use medical device that enables effective ventilation for patients in cardiac arrest.
Cardiology
Strasbourg, France
Cardio-Renal
Cardio-Renalsolution is a connected medical device that allows patients with chronic health conditions to measure their blood potassium levels at home. The cloud-based platform is accessible by physicians who can monitor the clinical status of their patients and optimize medication doses accordingly.
Women’s Health
Strasbourg, France
Fizimed
Fizimed is a start-up who has developed EMY, an innovative connected medical device to stop women’s urinary incontinence by re-educating the pelvic floor. EMY is a connected probe that allows you to train your perineum at home.
Anaesthesiology
Paris, France
HoopCare
Founded by an anesthesiologist, HoopCare (formerly Intelligence Anesthesia) develops medical applications to improve the evaluation and management of surgical patients. The applications include algorithms, decision support systems, monitoring processes, etc. a set of modules for optimal care.
WhiteLab Genomics
The startup has developed a software platform that leverages AI to accelerate the development of gene and cell therapies. These next-generation therapies based on DNA and RNA strategies are complex and expensive to develop. WhiteLab’s platform enables research labs and technology companies to find the best molecular strategies and be guided interactively through the different phases of drug development, resulting in accelerated R&D programs.
Mypl
MyPL develops a highly innovative patient data visualization solution. Designed with and for medical experts in oncology, their dashboard automatically reconstructs a patient’s clinical file, presenting his or her health data structured and qualified by the experts. This allows physicians to make more informed decisions and to propose more appropriate therapeutic choices in record time.
Nurea
Nurea has developed the PRAEVAorta solution which automates image analysis and provides the fastest and most accurate quantitative analysis of aortic diseases. It enables physicians to detect asymptomatic disease before cardiovascular events and to personalize diagnosis and follow-up.
Qubit Pharmaceutical
Qubit Pharmaceuticals is an innovative international company, spun off from CNAM, CNRS, the University of Texas at Austin, Sorbonne University and the University of Washington, and based in Paris. Qubit Pharmaceuticals is backed by over 20 years of award-winning R&D. Qubit Pharmaceuticals is backed by Quantonation, a leading quantum technology investment fund, in its mission to revolutionize the way drugs are developed and deliver safer, more effective medicines faster.
Satelia
Satelia Cardio is a medical device for remote monitoring which is 100% reimbursed by social security as part of the ETAPES program. It is prescribed by cardiologists and is intended for monitoring patients with heart failure. It is used in more than 100 centers in France.
Sonio
Sonio is an Artificial Intelligence software that guides sonographers and physicians during prenatal ultrasounds in order to optimize the screening and diagnosis of congenital anomalies and rare diseases.
Neurology, oncology, immunology
Paris, France
Metafora
Metafora is developing a unique and powerful in vitro diagnostic (IVD) platform capable of detecting and characterizing the energetics of a single cell for accurate and rapid diagnosis and feasible therapeutic follow-up. Metafora deciphers how cells use key nutrients to fuel their metabolism. Metafora’s innovation stems from research conducted in leading CNRS university laboratories, in close collaboration with healthcare providers.
Cardiology
Monistrol sur Loire, France
CMI Nov
CMI’NOV specializes in the design and development of medical devices for transcatheter cardiac surgery. CMI’Nov Mit’rep is a new generation, minimally invasive annuloplasty medical device. Mitral regurgitation is one of the most common and difficult to treat chronic heart diseases in humans.
Picture yourself in the neighborhood
We'd love to get to know you
Join us, we offer you an extraordinary chance to learn, develop and be part of an exciting experience, supported by a knowledgeable team.
Tell us your story